Literature DB >> 23053140

Prognostic value of HIF-1α expression during fractionated irradiation.

L Helbig1, A Yaromina, S N Sriramareddy, S Böke, L Koi, H D Thames, M Baumann, D Zips.   

Abstract

BACKGROUND AND
PURPOSE: Hypoxia and reoxygenation are important determinants of outcome after radiotherapy. HIF-1α is a key molecule involved in cellular response to hypoxia. HIF-1α expression levels have been shown to change after irradiation. The objective of the present study was to explore the prognostic value of HIF-1α expression during fractionated irradiation.
MATERIALS AND METHODS: Six human squamous cell carcinoma models xenografted in nude mice were analysed. Tumours were excised after 3, 5 and 10 fractions. HIF-1α expression was quantified by western blot. For comparative analysis, previously published data on local tumour control data and pimonidazole hypoxic fraction was used.
RESULTS: HIF-1α expression in untreated tumours exhibited intertumoural heterogeneity and did not correlate with pimonidazole hypoxic fraction. During fractionated irradiation the majority of tumour models exhibited a decrease in HIF-1α expression, whereas in UT-SCC-5 no change was observed. Neither kinetics nor expression levels during fractionated irradiation correlated with local tumour control.
CONCLUSION: Our data do not support the use of HIF-1α determined during treatment as a biomarker to predict outcome after fractionated irradiation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053140     DOI: 10.1007/s00066-012-0150-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  37 in total

Review 1.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

2.  The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.

Authors:  David L Schwartz; Garth Powis; Arun Thitai-Kumar; Yi He; James Bankson; Ryan Williams; Robert Lemos; Junghwan Oh; Andrei Volgin; Suren Soghomonyan; Ryuichi Nishii; Mian Alauddin; Uday Mukhopadhay; Zhenghong Peng; William Bornmann; Juri Gelovani
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

3.  Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts.

Authors:  Ala Yaromina; Theresa Kroeber; Andreas Meinzer; Simon Boeke; Howard Thames; Michael Baumann; Daniel Zips
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

4.  Regulation of HIF-1alpha stability through S-nitrosylation.

Authors:  Fang Li; Pierre Sonveaux; Zahid N Rabbani; Shanling Liu; Bin Yan; Qian Huang; Zeljko Vujaskovic; Mark W Dewhirst; Chuan-Yuan Li
Journal:  Mol Cell       Date:  2007-04-13       Impact factor: 17.970

5.  HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors.

Authors:  Hilde L K Janssen; Karin M G Haustermans; Debbie Sprong; Gerard Blommestijn; Ingrid Hofland; Frank J Hoebers; Elke Blijweert; James A Raleigh; Gregg L Semenza; Mahesh A Varia; Alfons J Balm; Marie Louise F van Velthuysen; Pierre Delaere; Raf Sciot; Adrian C Begg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

6.  Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors.

Authors:  Solmaz Sobhanifar; Christina Aquino-Parsons; Eric J Stanbridge; Peggy Olive
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

7.  Cell type-specific association of hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein accumulation and radiobiologic tumor hypoxia.

Authors:  Dirk Vordermark; Astrid Katzer; Kurt Baier; Peter Kraft; Michael Flentje
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

8.  Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia.

Authors:  Arnulf Mayer; Michael Höckel; Alexander Wree; Cornelia Leo; Lars-Christian Horn; Peter Vaupel
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

9.  Prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome after radiotherapy in oropharyngeal cancer.

Authors:  Priyamal Silva; Nick J Slevin; Philip Sloan; Helen Valentine; Jo Cresswell; David Ryder; Patricia Price; Jarrod J Homer; Catharine M L West
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-01       Impact factor: 7.038

10.  Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4.

Authors:  Saskia E Rademakers; Jasper Lok; Albert J van der Kogel; Johan Bussink; Johannes H A M Kaanders
Journal:  BMC Cancer       Date:  2011-05-12       Impact factor: 4.430

View more
  3 in total

Review 1.  [Experimental tumor therapy].

Authors:  M Baumann; D Zips; M Krause
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

2.  A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.

Authors:  C Ostheimer; M Bache; A Güttler; M Kotzsch; D Vordermark
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

3.  BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts.

Authors:  Linda Helbig; Lydia Koi; Kerstin Brüchner; Kristin Gurtner; Holger Hess-Stumpp; Kerstin Unterschemmann; Michael Baumann; Daniel Zips; Ala Yaromina
Journal:  Radiat Oncol       Date:  2014-09-19       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.